GELSOMINO, FRANCESCO
GELSOMINO, FRANCESCO
Dottorandi
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib
2024 Di Federico A.; De Giglio A.; Sperandi F.; Melotti B.; Ardizzoni A.; Gelsomino F.
From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)
2024 Fabbri L.; Di Federico A.; Astore M.; Marchiori V.; Rejtano A.; Seminerio R.; Gelsomino F.; De Giglio A.
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
2023 Sisi, Monia; Vitale, Giovanni; Fusaroli, Michele; Riefolo, Mattia; Giunchi, Valentina; D’Errico, Antonietta; Ardizzoni, Andrea; Raschi, Emanuel; Gelsomino, Francesco
Neurological Manifestations as a Harbinger of Myocarditis in Patients Treated With Immune Checkpoint Inhibitors
2023 Rossi, Simone; Cani, Ilaria; Raschi, Emanuel; Comito, Francesca; Rinaldi, Rita; Ardizzoni, Andrea; Guarino, Maria; Gelsomino, Francesco
Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis
2023 Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY
2023 Raschi E.; Comito F.; Massari F.; Gelsomino F.
A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale
2022 Andrini, Elisa; Lamberti, Giuseppe; Mazzoni, Francesca; Riccardi, Ferdinando; Bonetti, Andrea; Follador, Alessandro; Artioli, Fabrizio; Genova, Carlo; Barbieri, Fausto; Frassoldati, Antonio; Brighenti, Matteo; Colantonio, Ida; Pasello, Giulia; Ficorella, Corrado; Cinieri, Saverio; Tiseo, Marcello; Gelsomino, Francesco; Tognetto, Michele; Rihawi, Karim; Ardizzoni, Andrea
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC
2022 Ruzzi, Francesca; Angelicola, Stefania; Landuzzi, Lorena; Nironi, Elena; Semprini, Maria Sofia; Scalambra, Laura; Altimari, Annalisa; Gruppioni, Elisa; Fiorentino, Michelangelo; Giunchi, Francesca; Ferracin, Manuela; Astolfi, Annalisa; Indio, Valentina; Ardizzoni, Andrea; Gelsomino, Francesco; Nanni, Patrizia; Lollini, Pier-Luigi; Palladini, Arianna
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes
2022 Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; De Biase, Dario; Giunchi, Francesca; Palladini, Arianna; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea
Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
2022 De Giglio, Andrea; Aprile, Marta; Di Federico, Alessandro; Sperandi, Francesca; Melotti, Barbara; Gelsomino, Francesco; Ardizzoni, Andrea
Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC
2022 Dall'Olio, Filippo G; Parisi, Claudia; Marcolin, Laura; Brocchi, Stefano; Caramella, Caroline; Conci, Nicole; Carpani, Giulia; Gelsomino, Francesco; Ardizzoni, Stefano; Marchese, Paola Valeria; Paccapelo, Alexandro; Grilli, Giada; Golfieri, Rita; Besse, Benjamin; Ardizzoni, Andrea
Paraneoplastic vs. non-paraneoplastic anti-Hu associated dysmotility: a case series and literature review
2022 Rossi, Simone; Merli, Elena; Rinaldi, Rita; Deleonardi, Gaia; Mastrangelo, Vincenzo; Sasdelli, Anna Simona; Di Federico, Alessandro; Guarino, Maria; Donadio, Vincenzo; Pironi, Loris; Gelsomino, Francesco; De Giorgio, Roberto; D'Angelo, Roberto
Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience
2022 De Giglio, Andrea; Grandinetti, Valeria; Aprile, Marta; Borelli, Greta; Campus, Anita; Croci Chiocchini, Anna Laura; Busutti, Marco; Vischini, Gisella; Di Federico, Alessandro; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea; La Manna, Gaetano; Gelsomino, Francesco
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy
2022 De Giglio, Andrea; Tassinari, Elisa; Zappi, Arianna; Di Federico, Alessandro; Lenzi, Barbara; Sperandi, Francesca; Melotti, Barbara; Gelsomino, Francesco; Maltoni, Marco; Ardizzoni, Andrea
Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) (British Journal of Cancer, (2020), 123, 1, (26-32), 10.1038/s41416-020-0845-3)
2021 Gelsomino F.; Tiseo M.; Barbieri F.; Riccardi F.; Cavanna L.; Frassoldati A.; Delmonte A.; Longo L.; Dazzi C.; Cinieri S.; Colantonio I.; Sperandi F.; Lamberti G.; Brocchi S.; Tofani L.; Boni L.; Ardizzoni A.
Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches
2021 Laprovitera N.; Salamon I.; Gelsomino F.; Porcellini E.; Riefolo M.; Garonzi M.; Tononi P.; Valente S.; Sabbioni S.; Fontana F.; Manaresi N.; D'Errico A.; Pantaleo M.A.; Ardizzoni A.; Ferracin M.
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis
2021 Di Federico A.; De Giglio A.; Nuvola G.; Deiana C.; Conci N.; Gelsomino F.; Ardizzoni A.
PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy
2021 Di Federico A.; De Giglio A.; Parisi C.; Gelsomino F.; Ardizzoni A.
PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors
2021 Dall'Olio F.G.; Gelsomino F.; Conci N.; Marcolin L.; De Giglio A.; Grilli G.; Sperandi F.; Fontana F.; Terracciano M.; Fragomeno B.; Tober N.; Manferrari G.; Brocchi S.; Golfieri R.; Fiorentino M.; Ardizzoni A.
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors
2021 Minari R.; Bonatti F.; Mazzaschi G.; Dodi A.; Facchinetti F.; Gelsomino F.; Cinquegrani G.; Squadrilli A.; Bordi P.; Buti S.; Bersanelli M.; Leonetti A.; Cosenza A.; Ferri L.; Rapacchi E.; Quaini F.; Ardizzoni A.; Tiseo M.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib | Di Federico A.; De Giglio A.; Sperandi F.; Melotti B.; Ardizzoni A.; Gelsomino F. | 2024-01-01 | ANTI-CANCER DRUGS | - | 1.01 Articolo in rivista | - |
| From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC) | Fabbri L.; Di Federico A.; Astore M.; Marchiori V.; Rejtano A.; Seminerio R.; Gelsomino F.; De Gi...glio A. | 2024-01-01 | DIAGNOSTICS | - | 1.01 Articolo in rivista | diagnostics-14-00048-v2.pdf |
| Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors | Sisi, Monia; Vitale, Giovanni; Fusaroli, Michele; Riefolo, Mattia; Giunchi, Valentina; D’Errico, ...Antonietta; Ardizzoni, Andrea; Raschi, Emanuel; Gelsomino, Francesco | 2023-01-01 | JTO CLINICAL AND RESEARCH REPORTS | - | 1.01 Articolo in rivista | Sisi et al. JTO CCR 23.pdf; Sisi et al. JTO CCR supplementary 23.pdf |
| Neurological Manifestations as a Harbinger of Myocarditis in Patients Treated With Immune Checkpoint Inhibitors | Rossi, Simone; Cani, Ilaria; Raschi, Emanuel; Comito, Francesca; Rinaldi, Rita; Ardizzoni, Andrea...; Guarino, Maria; Gelsomino, Francesco | 2023-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 1.04 Replica / breve intervento (e simili) | - |
| Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis | Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; Sperandi, Francesca; Melotti, B...arbara; Ardizzoni, Andrea | 2023-01-01 | JOURNAL OF THE NATIONAL CANCER INSTITUTE | - | 1.01 Articolo in rivista | - |
| Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY | Raschi E.; Comito F.; Massari F.; Gelsomino F. | 2023-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| A phase II, open-label, single arm, trial of carboplatin plus etoposide with bevacizumab and atezolizumab in patients with extended-stage small-cell lung cancer (CeLEBrATE study): background, design and rationale | Andrini, Elisa; Lamberti, Giuseppe; Mazzoni, Francesca; Riccardi, Ferdinando; Bonetti, Andrea; Fo...llador, Alessandro; Artioli, Fabrizio; Genova, Carlo; Barbieri, Fausto; Frassoldati, Antonio; Brighenti, Matteo; Colantonio, Ida; Pasello, Giulia; Ficorella, Corrado; Cinieri, Saverio; Tiseo, Marcello; Gelsomino, Francesco; Tognetto, Michele; Rihawi, Karim; Ardizzoni, Andrea | 2022-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC | Ruzzi, Francesca; Angelicola, Stefania; Landuzzi, Lorena; Nironi, Elena; Semprini, Maria Sofia; S...calambra, Laura; Altimari, Annalisa; Gruppioni, Elisa; Fiorentino, Michelangelo; Giunchi, Francesca; Ferracin, Manuela; Astolfi, Annalisa; Indio, Valentina; Ardizzoni, Andrea; Gelsomino, Francesco; Nanni, Patrizia; Lollini, Pier-Luigi; Palladini, Arianna | 2022-01-01 | TRANSLATIONAL LUNG CANCER RESEARCH | - | 1.01 Articolo in rivista | ADK-VR2 TLCR.pdf; tlcr-11-11-2216-coif.zip |
| Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes | Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; De Biase, Dario; Giunchi, Franc...esca; Palladini, Arianna; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-14-03472-v2.pdf; cancers-14-03472-s001.zip |
| Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) | De Giglio, Andrea; Aprile, Marta; Di Federico, Alessandro; Sperandi, Francesca; Melotti, Barbara;... Gelsomino, Francesco; Ardizzoni, Andrea | 2022-01-01 | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | - | 1.01 Articolo in rivista | ijms-23-10292.pdf |
| Monitoring tumor growth rate to predict immune checkpoint inhibitors' treatment outcome in advanced NSCLC | Dall'Olio, Filippo G; Parisi, Claudia; Marcolin, Laura; Brocchi, Stefano; Caramella, Caroline; Co...nci, Nicole; Carpani, Giulia; Gelsomino, Francesco; Ardizzoni, Stefano; Marchese, Paola Valeria; Paccapelo, Alexandro; Grilli, Giada; Golfieri, Rita; Besse, Benjamin; Ardizzoni, Andrea | 2022-01-01 | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | - | 1.01 Articolo in rivista | 12. Dall'Olio_Monitoring Tumor Growth Rate to predict Immune Checkpoint Inhibitors’ treatment outcome in advanced NSCLC.pdf |
| Paraneoplastic vs. non-paraneoplastic anti-Hu associated dysmotility: a case series and literature review | Rossi, Simone; Merli, Elena; Rinaldi, Rita; Deleonardi, Gaia; Mastrangelo, Vincenzo; Sasdelli, An...na Simona; Di Federico, Alessandro; Guarino, Maria; Donadio, Vincenzo; Pironi, Loris; Gelsomino, Francesco; De Giorgio, Roberto; D'Angelo, Roberto | 2022-01-01 | JOURNAL OF NEUROLOGY | - | 1.01 Articolo in rivista | - |
| Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience | De Giglio, Andrea; Grandinetti, Valeria; Aprile, Marta; Borelli, Greta; Campus, Anita; Croci Chio...cchini, Anna Laura; Busutti, Marco; Vischini, Gisella; Di Federico, Alessandro; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea; La Manna, Gaetano; Gelsomino, Francesco | 2022-01-01 | LUNG CANCER | - | 1.01 Articolo in rivista | - |
| The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy | De Giglio, Andrea; Tassinari, Elisa; Zappi, Arianna; Di Federico, Alessandro; Lenzi, Barbara; Spe...randi, Francesca; Melotti, Barbara; Gelsomino, Francesco; Maltoni, Marco; Ardizzoni, Andrea | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | cancers-14-05845-v2.pdf |
| Correction to: Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL) (British Journal of Cancer, (2020), 123, 1, (26-32), 10.1038/s41416-020-0845-3) | Gelsomino F.; Tiseo M.; Barbieri F.; Riccardi F.; Cavanna L.; Frassoldati A.; Delmonte A.; Longo ...L.; Dazzi C.; Cinieri S.; Colantonio I.; Sperandi F.; Lamberti G.; Brocchi S.; Tofani L.; Boni L.; Ardizzoni A. | 2021-01-01 | BRITISH JOURNAL OF CANCER | - | 1.04 Replica / breve intervento (e simili) | - |
| Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches | Laprovitera N.; Salamon I.; Gelsomino F.; Porcellini E.; Riefolo M.; Garonzi M.; Tononi P.; Valen...te S.; Sabbioni S.; Fontana F.; Manaresi N.; D'Errico A.; Pantaleo M.A.; Ardizzoni A.; Ferracin M. | 2021-01-01 | FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | - | 1.01 Articolo in rivista | 2021_Laprovitera-fcell-09-666156.pdf; Supplementary Material.zip |
| PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis | Di Federico A.; De Giglio A.; Nuvola G.; Deiana C.; Conci N.; Gelsomino F.; Ardizzoni A. | 2021-01-01 | FUTURE ONCOLOGY | - | 1.01 Articolo in rivista | - |
| PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy | Di Federico A.; De Giglio A.; Parisi C.; Gelsomino F.; Ardizzoni A. | 2021-01-01 | CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | - | 1.01 Articolo in rivista | - |
| PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors | Dall'Olio F.G.; Gelsomino F.; Conci N.; Marcolin L.; De Giglio A.; Grilli G.; Sperandi F.; Fontan...a F.; Terracciano M.; Fragomeno B.; Tober N.; Manferrari G.; Brocchi S.; Golfieri R.; Fiorentino M.; Ardizzoni A. | 2021-01-01 | CLINICAL LUNG CANCER | - | 1.01 Articolo in rivista | - |
| PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors | Minari R.; Bonatti F.; Mazzaschi G.; Dodi A.; Facchinetti F.; Gelsomino F.; Cinquegrani G.; Squad...rilli A.; Bordi P.; Buti S.; Bersanelli M.; Leonetti A.; Cosenza A.; Ferri L.; Rapacchi E.; Quaini F.; Ardizzoni A.; Tiseo M. | 2021-01-01 | TUMORI | - | 1.01 Articolo in rivista | - |